Stroke stop
Pro Research Analysisby 
Searched over 200M research papers for "stroke stop"
Consensus Meter
Stroke Prevention and Management: Insights from Recent Research
Stroke Prevention in Sickle Cell Anemia: The STOP Trials
Chronic Transfusion for Stroke Prevention
The Stroke Prevention Trial in Sickle Cell Anemia (STOP) was a landmark study that demonstrated the efficacy of chronic transfusion in preventing initial strokes in children with sickle cell anemia who were identified as high-risk through transcranial Doppler (TCD) screening. The trial was halted early due to the significant benefits observed in the transfusion group, where 70% of patients opted for transfusion compared to 45% in the standard care group. Despite the benefits, some patients with persistently abnormal TCD results still developed strokes, highlighting the need for continuous monitoring and further research into predictive features for stroke risk.
Long-Term Follow-Up and TCD Screening
Extended follow-up of the STOP trial participants revealed that patients on transfusion therapy were more likely to have normal TCD results over time. However, iron overload and alloimmunization were noted as side effects of chronic transfusion. The study underscored the importance of persistent TCD elevation as a signal for ongoing stroke risk and suggested that some patients might experience a reduction in TCD velocities without transfusion, warranting further investigation.
Conversion to High Risk and Stroke Incidence
The STOP study also screened over 2000 children with TCD to identify those at high risk for stroke. It was found that children with abnormal TCD results had a significantly higher risk of stroke compared to those with normal or conditional TCD results. Younger children and those with higher initial flow velocities were more likely to convert to abnormal TCDs upon rescreening, confirming the predictive value of TCD for stroke risk in this population.
Post-STOP Era and Implementation Challenges
In the post-STOP era, the incidence of ischemic stroke among former STOP trial participants was assessed. The study found that most strokes occurred in patients who were not properly screened or adequately transfused according to the STOP protocol. This highlights the need for better implementation of the STOP guidelines to prevent ischemic strokes in children with sickle cell disease.
Secondary Stroke Prevention in Underserved Populations
Multibehavioral Self-Care Interventions
A pilot intervention aimed at improving secondary stroke self-care among underserved ethnic minority individuals showed promising results. The STOP program, which included culturally tailored information sessions and goal-setting activities, significantly improved stroke knowledge, reduced tobacco use, and moderated the effects of anxiety on tobacco use. These findings suggest that such interventions could be effective in reducing secondary stroke risk factors in underserved populations and should be tested in larger trials.
Acute Stroke Management: Antihypertensive Treatment and Care Coordination
Antihypertensive Treatment Post-Stroke
The Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS) investigated whether continuing or stopping pre-existing antihypertensive treatment in the immediate post-stroke period affected outcomes. The study found no significant differences in death or dependency rates, cardiovascular events, or mortality at six months between the groups. These results suggest that continuing antihypertensive treatment post-stroke does not adversely affect patient outcomes, although further research is needed due to the early termination of the trial.
Care Coordination Applications
The implementation of the STOP STROKE© medical application significantly improved door-to-needle (DTN) times for patients with acute ischemic stroke (AIS). Studies showed a reduction in mean DTN times and an increase in the percentage of patients treated within 60 minutes of arrival. This improvement in coordination and communication during emergency stroke care highlights the potential of such applications to enhance stroke treatment outcomes .
Conclusion
The STOP trials have significantly advanced our understanding of stroke prevention in sickle cell anemia, emphasizing the importance of TCD screening and chronic transfusion. However, challenges in implementation remain. Additionally, secondary stroke prevention programs tailored for underserved populations and innovative care coordination applications show promise in improving stroke outcomes. Continued research and better implementation of existing protocols are essential to further reduce stroke incidence and improve patient care.
Sources and full results
Most relevant research papers on this topic